Future therapy for hepatitis B virus infection

详细信息    查看全文

• 作者：Masahito Minami
• 关键词：Nucleoside analogue ; Cyclosporine ; APOBEC3 ; RNA interference ; Peptide vaccine
• 刊名：Clinical Journal of Gastroenterology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：8
• 期：4
• 页码：167-171
• 全文大小：527 KB
• 参考文献：1.Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172-0.CrossRef PubMed <br>2.Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2004;3:188-3.PubMed <br>3.Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276-2.CrossRef PubMed <br>4.Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714-2.CrossRef PubMed <br>5.Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185-5.CrossRef PubMed <br>6.Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mito- chondrial DNA. Hepatology. 2009;49:2080-.CrossRef PubMed <br>7.van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and ala- nine aminotransferase. Gut. 2003;52:420-.PubMed Central CrossRef PubMed <br>8.European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-2.CrossRef <br>9.Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118-9.CrossRef PubMed <br>10.Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-.CrossRef PubMed <br>11.Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology 2014;57:151-.<br>12.Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26:335-1.CrossRef PubMed <br>13.Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070-3.CrossRef PubMed <br>14.Watashi K, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014;15:2892-05.PubMed Central CrossRef PubMed <br>15.Gallay P, Chatterji U, Bobardt M, Ure D, Trepanier D, Foster R, et al. Novel cyclophilin inhibitor CPI-431-32 shows broad spectrum antiviral activity by blocking replication of HCV, HBV, and HIV-1 viruses. J Hepatol. 2015;62:S677 (Abstract P0890).CrossRef <br>16.Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013;57:5291-.PubMed Central CrossRef PubMed <br>17.Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Vaillant A, et al. Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2015;62:S257- (Abstract LO2).CrossRef <br>18.Jansen L, Vaillant A, Stelma F, Kootstra NA, Bazinet M, Al-Mahtabet M, et al. Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP 2139-Ca. J Hepatol. 2015;62:S250 (Abstract O114).CrossRef <br>19.Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocasids. Science. 2003;299:893-.CrossRef PubMed <br>20.Wu G, Liu B, Li J, Arzumanyan A, Clayton MM, Schinazi RF, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 2013;57:5344-4.PubMed Central CrossRef PubMed <br>21.Klumpp K, Shimada T, Allweiss L, Volz T, Luetgehetman M, Flores O, et al. High antiviral activitiy of the HBV core inhibitor NVR 3-778 in the humanized UPA/SCID mouse model. J Hepatol. 2015;62:S250 (Abstract O115).CrossRef <br>22.Korolowicz K, Czerwinski S, Iyer R, Skell J, Yang J, Tucker R, et al. Antiviral efficacy and induction of host immune responses with SB9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic hepatitis B (HBV) infection. J Hepatol. 2015;62:S557 (Abstract P0636).CrossRef <br>23.Benetatos CA, Mitsuuchi Y, Burns JM, Meiman EM, Condon SM, Yu G, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014;13:867-9.CrossRef PubMed <br>24.Lanford RE, Guerra B, Chavez D, Giavedoni L
• 作者单位：Masahito Minami (1) (2) <br><br>1. Aiseikai Yamashina Hospital, Kyoto, Japan <br> 2. Molecular Gastroenterology and Hepatology, Department of Medicine, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan <br>
• 刊物主题：Gastroenterology; Hepatology; Abdominal Surgery; Colorectal Surgery; Surgical Oncology;
• 出版者：Springer Japan
• ISSN：1865-7265

文摘

We can now control hepatitis B virus infection by continuously administering nucleoside and nucleotide analogues such as entecavir and tenofovir. These drugs are generally safe and sufficiently effective, but future drugs are needed that can show off-treatment efficacy—in other words, eradication of latent hepatitis B virus DNA (covalently closed circular DNA) in the hepatocytes. This article is an overview of new drugs under development and some novel strategies to inhibit hepatitis B virus proliferation. Keywords Nucleoside analogue Cyclosporine APOBEC3 RNA interference Peptide vaccine